Item 2.02 Results of Operation and Financial Condition.
On February 28, 2022, Krystal Biotech, Inc., a Delaware corporation (the
"Company"), announced its fiscal year 2021 financial results. A copy of the
Company's press release is attached as Exhibit 99.1 hereto and incorporated by
reference herein.
The information concerning financial results in this Form 8-K and in Exhibit
99.1 shall not be deemed to be "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section. The information concerning financial results in
this Form 8-K and in Exhibit 99.1 shall not be incorporated into any
registration statement or other document filed with the Securities and Exchange
Commission by the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing, except as shall
be expressly set forth by specific reference in such filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Appointment of President, R&D
Effective February 25, 2022, the board of directors of the Company appointed Ms.
Suma M. Krishnan, the Company's current Chief Operating Officer, as the
Company's President, R&D.
Suma M. Krishnan, 56, is the Company's founder and has served as a director and
its Chief Operating Officer since its inception. She previously served as Senior
Vice President and head of the Human Therapeutics Division, as well as Senior
Vice President of Regulatory Affairs at Intrexon Corporation from 2012 to 2016.
She previously served as Senior Vice President, Product Development at Pinnacle
Pharmaceuticals, Inc. from 2009 to 2011. Prior to joining Pinnacle, Ms. Krishnan
was Vice President, Product Development at New River Pharmaceuticals, Inc. from
2002 until its acquisition by Shire plc in 2007. Prior to New River, Ms.
Krishnan held roles at Pfizer, Inc.; the Weinberg Group; and Janssen
Pharmaceuticals, Inc. Ms. Krishnan received an M.S. in Organic Chemistry from
Villanova University, an M.B.A. from Institute of Management and Research
(India) and an undergraduate degree in Organic Chemistry from Ferguson
University (India). Ms. Krishnan is the spouse of Krish Krishnan, our Chairman
and Chief Executive Officer.
There are no arrangements or understandings between Ms. Krishnan and any other
person pursuant to which she was appointed as our President, R&D. Other than as
disclosed in this Report, Ms. Krishnan does not have any family relationship
with any director or officer of the Company or any person nominated or chosen by
the Company to become a director or officer. There are no transactions in which
Ms. Krishnan has an interest requiring disclosure under Item 404(a) of
Regulation S-K.
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release, dated February 28, 2022.
104 Cover Page Interactive Data file (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
KRYSTAL BIOTECH, INC. 
